SillaJen (215600) has been named to the list of selected research and development projects for the second round of the 2026 National New Drug Development Program. According to the results of the '2026 Second Round National New Drug Development Project Selection' announced by the Korea Drug Development Fund (KDDF) on the 8th, SillaJen was included among the selected institutions in the 'New Drug R&D Ecosystem Building Research (Candidate Substance)' category. SillaJen's project number listed in the announcement is RS-2026-25616967.

This selection is a notable milestone for SillaJen, which has been pursuing research and development of new drug candidate substances. However, the selection announcement alone makes it difficult to determine the specific research targets, development stage, scale of support, or future commercialization potential.

◆ Remaining Procedures Until Contract Signing Even after the announcement of the selection results, procedures such as signing the agreement and submitting a revised plan remain for this project. The program office will provide guidance on the relevant schedule and detailed procedures later.

Certain restrictions also apply to public announcements by selected institutions. Before the agreement is signed, announcements via press releases, interviews, or websites are prohibited, and even after the agreement, announcements through mass media require prior consultation with the program office. Therefore, whether this project selection will translate into tangible outcomes in the actual R&D process will need to be confirmed through the future agreement signing and research progress.

◆ Shares Close at 2,320 Won... Intraday Drop to 2,300 Won SillaJen's stock finished after-hours trading at 2,320 won on the 8th. This was 60 won below the reference price of 2,380 won, a decline of 2.52%. The opening price that day was 2,380 won, and the intraday high also stayed at 2,380 won, while the low was recorded at 2,300 won. The 52-week high is 5,400 won and the low is 1,780 won.

While it is worth examining the project selection announcement alongside the stock price movement, there is no confirmed evidence that this announcement directly caused the day's share price decline.

Going forward, market attention is expected to shift beyond the project selection itself to the specific contents of the R&D and subsequent outcomes. It remains to be seen what significance participation in the National New Drug Development Program will hold for SillaJen's drug development strategy.

[Stock price information is based on after-market closing prices as of October 8, 2026, and is not intended as investment solicitation. Investment decisions and responsibilities rest with the investor. This article was written with the assistance of AI.]